JPWO2021176094A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021176094A5 JPWO2021176094A5 JP2022553063A JP2022553063A JPWO2021176094A5 JP WO2021176094 A5 JPWO2021176094 A5 JP WO2021176094A5 JP 2022553063 A JP2022553063 A JP 2022553063A JP 2022553063 A JP2022553063 A JP 2022553063A JP WO2021176094 A5 JPWO2021176094 A5 JP WO2021176094A5
- Authority
- JP
- Japan
- Prior art keywords
- pick1
- inhibitor
- seq
- peptide
- inhibitor according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims description 6
- 101000604540 Homo sapiens PRKCA-binding protein Proteins 0.000 claims 31
- 102100038730 PRKCA-binding protein Human genes 0.000 claims 31
- 239000003112 inhibitor Substances 0.000 claims 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 125000001931 aliphatic group Chemical group 0.000 claims 11
- 239000000693 micelle Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000004454 Hyperalgesia Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- UACIBCPNAKBWHX-CTBOZYAPSA-N gonane Chemical compound C1CCC[C@@H]2[C@H]3CC[C@@H]4CCC[C@H]4[C@@H]3CCC21 UACIBCPNAKBWHX-CTBOZYAPSA-N 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20161493.0 | 2020-03-06 | ||
| EP20161493 | 2020-03-06 | ||
| PCT/EP2021/055678 WO2021176094A1 (fr) | 2020-03-06 | 2021-03-05 | Inhibiteurs peptidiques conjugués à des lipides de pi1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506598A JP2023506598A (ja) | 2023-02-16 |
| JPWO2021176094A5 true JPWO2021176094A5 (fr) | 2024-03-14 |
Family
ID=69780027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553063A Pending JP2023506598A (ja) | 2020-03-06 | 2021-03-05 | Ｐｉｃｋ１の脂質共役ペプチド阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230346948A1 (fr) |
| EP (1) | EP4114524A1 (fr) |
| JP (1) | JP2023506598A (fr) |
| KR (1) | KR20220150313A (fr) |
| CN (1) | CN115362001A (fr) |
| AU (1) | AU2021232645A1 (fr) |
| BR (1) | BR112022017673A2 (fr) |
| CA (1) | CA3168324A1 (fr) |
| MX (1) | MX2022011051A (fr) |
| WO (1) | WO2021176094A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008101160A2 (fr) * | 2007-02-16 | 2008-08-21 | Genentech, Inc. | Modulateurs de htra1-pdz et de htra3-pdz |
| DK3074032T3 (en) | 2013-12-01 | 2019-04-15 | Univ Copenhagen | Fatty acid derivatives of dimeric PSD-95 inhibitors |
| US20210347821A1 (en) | 2018-10-22 | 2021-11-11 | University Of Copenhagen | Inhibitors of pick1 and uses thereof |
-
2021
- 2021-03-05 CA CA3168324A patent/CA3168324A1/fr active Pending
- 2021-03-05 MX MX2022011051A patent/MX2022011051A/es unknown
- 2021-03-05 WO PCT/EP2021/055678 patent/WO2021176094A1/fr unknown
- 2021-03-05 US US17/905,660 patent/US20230346948A1/en active Pending
- 2021-03-05 BR BR112022017673A patent/BR112022017673A2/pt unknown
- 2021-03-05 JP JP2022553063A patent/JP2023506598A/ja active Pending
- 2021-03-05 EP EP21709689.0A patent/EP4114524A1/fr active Pending
- 2021-03-05 AU AU2021232645A patent/AU2021232645A1/en active Pending
- 2021-03-05 KR KR1020227031597A patent/KR20220150313A/ko unknown
- 2021-03-05 CN CN202180027127.0A patent/CN115362001A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6386609B2 (ja) | エキノキャンディン系化合物のための投与レジメン | |
| US10335455B2 (en) | Method for prevention or treatment of intractable inflammatory bowel disease | |
| JP2001513514A (ja) | 少なくとも１種の二重鎖ＲＮＡ（ｄｓＲＮＡ）を、少なくとも１種の抗ウイルス剤と組合せて含有する製品 | |
| US8409580B2 (en) | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers | |
| JPH07252162A (ja) | サイクロスポリンを含有する液体製剤とその調製方法 | |
| EP0593585B1 (fr) | Peptide neutralisant la toxicite du facteur de necrose tumorale alpha (fnt) et la toxicite des lipopolysaccharides (lps) | |
| JP2008521840A5 (fr) | ||
| JP2002506833A (ja) | 治療薬のｉｎｖｉｖｏデリバリー用担体 | |
| JP2001513550A5 (fr) | ||
| EP2545934B1 (fr) | Des compositions nutraceutiques contenant de l'aequorine | |
| JPH0466454B2 (fr) | ||
| JP2024010060A (ja) | エキノカンジン抗真菌剤の合成 | |
| JP6285447B2 (ja) | 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸 | |
| CN107760661A (zh) | 药用激肽原酶的peg修饰物及其制备方法和应用 | |
| US20050244419A1 (en) | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers | |
| AU2004262472B2 (en) | Targeted therapeutic vaccine against P-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers | |
| JPWO2021176094A5 (fr) | ||
| US20050255561A1 (en) | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers | |
| WO2007013677A1 (fr) | Potentialisateur pour substance ayant un effet semblable à celui de l'interféron | |
| EP3329930A1 (fr) | Compositions pharmaceutiques | |
| CA2378778A1 (fr) | Antagonistes de l'interleukine-16 | |
| JP2003507011A5 (fr) | ||
| JP2006522808A5 (fr) | ||
| JP4362780B2 (ja) | アナフィラトキシンＣ５ａを不活性化するペプチド | |
| JP2023533797A (ja) | 脂質複合体を含む経口医薬組成物 |